Zevra Therapeutics, Inc. (NASDAQ: ZVRA)

$10.83 ▲ +0.03 (+0.23%)

As of May 12, 2026 12:12 PM

Sector: Healthcare Industry: Biotechnology CIK: 0001434647

Market Cap 565.83 Mn

P/E 7.47

P/S 5.31

Div. Yield 0.00

ROIC (Qtr) -0.29

Total Debt (Qtr) 61.93 Mn

Revenue Growth (1y) (Qtr) 183.89

Add ratio to table...

About

Zevra Therapeutics Inc is a commercial-stage company focused on bringing life-changing therapies to people living with rare diseases. The company is committed to expanding patient access progressing its pipeline toward key milestones and delivering meaningful therapeutics. Zevra Therapeutics Inc operates through disciplined execution of its strategic plan guided by core values including patient centricity integrity accountability innovation and courage. The company has built a diverse portfolio of products and product candidates through internal...

Zevra Therapeutics Inc is a commercial-stage company focused on bringing life-changing therapies to people living with rare diseases. The company is committed to expanding patient access progressing its pipeline toward key milestones and delivering meaningful therapeutics. Zevra Therapeutics Inc operates through disciplined execution of its strategic plan guided by core values including patient centricity integrity accountability innovation and courage. The company has built a diverse portfolio of products and product candidates through internal development and strategic investments via acquisition. Zevra Therapeutics Inc is transforming into a leading rare-disease company by prioritizing the commercialization and global expansion of its lead product MIPLYFFA while maintaining OLPRUVA as commercially available and advancing the development of its clinical stage asset celiprolol.

Zevra Therapeutics Inc generates revenue primarily from the sale of its approved commercial products MIPLYFFA and OLPRUVA as well as through royalty and milestone payments from partnered products such as AZSTARYS. The company receives quarterly tiered royalty payments based on a percentage of net sales from its collaboration and license agreement with Commave for AZSTARYS. Zevra Therapeutics Inc also earns revenue from the sale of OLPRUVA in the United States which it began generating in the fourth quarter of 2023. The company does not currently generate revenue from MIPLYFFA in the United States as it received FDA approval in September 2024 and became commercially available for dispense in November 2024 with commercial ramp-up underway. Revenue is derived from selling therapies to patients suffering from rare diseases including Niemann-Pick disease type C urea cycle disorders and vascular Ehlers-Danlos syndrome through specialty pharmacy distribution channels and arrangements with third parties for marketing sales medical affairs distribution and other non-technical capabilities.

The company operates through the following segments: MIPLYFFA OLPRUVA Celiprolol KP1077 and AZSTARYS.

• MIPLYFFA is an orally-delivered treatment for Niemann-Pick disease type C indicated for use in combination with miglustat for the treatment of neurological manifestations in adult and pediatric patients two years of age and older. It received FDA approval in September 2024 and became commercially available in the United States in November 2024. Zevra Therapeutics Inc holds global rights to develop and commercialize MIPLYFFA and has filed a Marketing Authorization Application with the European Medicines Agency which is currently under review. The product is also being made available to patients in France Germany and other EU member states through an expanded access program.

• OLPRUVA is a proprietary and novel formulation of sodium phenylbutyrate powder packaged in pre-measured single-dose envelopes approved in the United States as adjunctive therapy to standard of care for the chronic management of urea cycle disorders involving deficiencies of carbamylphosphate synthetase ornithine transcarbamylase or argininosuccinic acid synthetase. Zevra Therapeutics Inc began generating revenue from OLPRUVA sales in the United States in the fourth quarter of 2023 and has a partnership with Relief Therapeutics SA which holds exclusive development and commercialization rights for OLPRUVA in Geographical Europe.

• Celiprolol is an investigational product candidate being advanced for the treatment of Vascular Ehlers-Danlos syndrome in patients with a confirmed type III collagen mutation. Zevra Therapeutics Inc is actively enrolling a Phase 3 clinical trial known as DiSCOVER to determine whether celiprolol reduces the risk of clinical events in patients with VEDS. The drug has received Orphan Drug designation and Breakthrough Therapy designation from the FDA and is generally protected by U. S. patents with expiration potential through 2038.

• KP1077 utilizes serdexmethylphenidate a proprietary prodrug of d-methylphenidate as its active pharmaceutical ingredient and is being developed and evaluated for the treatment of Idiopathic Hypersomnia and narcolepsy. Zevra Therapeutics Inc completed a Phase 2 clinical trial for KP1077 in March 2024 which provided meaningful information on optimal dose and dosing regimen to inform Phase 3 trial design. The product has been granted orphan drug designation by the FDA for the treatment of Idiopathic Hypersomnia.

• AZSTARYS contains d-MPH and serdexmethylphenidate and is approved by the FDA as a once-daily treatment for attention deficit hyperactivity disorder in patients age six years and older. Zevra Therapeutics Inc markets AZSTARYS in the United States under a collaboration and license agreement with Commave under which it receives quarterly tiered royalty payments based on net sales and milestone payments. Corium an affiliate of Commave leads all commercialization activities for AZSTARYS in the United States.

Zevra Therapeutics Inc operates in the rare disease therapeutics industry where it faces competition from other pharmaceutical and biotechnology companies developing treatments for similar indications. For MIPLYFFA the company competes with AQNEURSA approved by IntraBio Inc for the treatment of neurological manifestations of Niemann-Pick disease type C. For OLPRUVA the company competes against branded and generic forms of phenylbutyrate including RAVICTI marketed by Amgen Inc and PHEBURANE marketed by Medunik USA. For celiprolol there are currently no approved therapies anywhere in the world for Vascular Ehlers-Danlos syndrome though the drug has become standard of care in some European countries when prescribed off label. For KP1077 the company anticipates competition from XYWAV marketed by Jazz Pharmaceuticals and other products in development for Idiopathic Hypersomnia. For AZSTARYS the company competes against currently marketed branded and generic methylphenidate products for ADHD including CONCERTA QUELBREE QUILLIVANT XR QUILLICHEW ER RITALIN FOCALIN FOCALIN XR METADATE CD DAYTRANA CONTEMPLA XR-ODT JORNAY PM and ADHANSIA XR. Zevra Therapeutics Inc differentiates itself through its focus on rare diseases with limited or no treatment options its proprietary Ligand Activated Technology platform and its strategic acquisitions that have expanded its pipeline and commercial footprint.

Zevra Therapeutics Inc serves patients diagnosed with rare diseases including Niemann-Pick disease type C urea cycle disorders vascular Ehlers-Danlos syndrome Idiopathic Hypersomnia narcolepsy and attention deficit hyperactivity disorder. The company works with prescribing clinicians healthcare providers and specialty pharmacy distributors to reach its patient base. Zevra Therapeutics Inc has established promotional programs such as Quick Start a thirty-day free trial program and patient co-pay programs to drive awareness and ensure access to its therapies. The company does not disclose specific customer names such as individual hospitals or healthcare organizations in the filing but serves patients through arrangements with third-party distributors and specialty pharmacy providers for the sale of its approved products.

Investment thesis

Bull case

MyPlayFa’s commercial trajectory in the U.S. demonstrates a clear upside trajectory, with 66% of diagnosed NPC patients achieving covered life status within a single year of launch. The rapid acceleration of reimbursement from months to weeks, even reaching 24‑hour turnaround for certain payers, signals a strengthening payer ecosystem that can sustain high utilization rates. The company’s investment in physician education and an AI‑driven patient‑identification platform is already yielding a higher proportion of newly diagnosed patients, a demographic that can amplify sales volume as awareness spreads across community practices. This momentum, coupled with a disciplined reduction in operating and R&D expenses, has slashed net losses from $33.2 million to a modest $0.01 per share, indicating that cash burn is being tamed while revenue grows. {bullet} The European expansion presents a catalyst that management has under‑promoted but is already gaining traction through the EMA validation and a 92‑patient global EAP. With an estimated 1,100 NPC patients in the region, the potential addressable market exceeds the U.S. base by a factor of 1.2, yet the presence of a mature miglustat therapy provides a receptive environment for a disease‑modifying alternative. A patent term extension request, if granted, could prolong exclusivity beyond orphan exclusivity, giving the company a regulatory shield that enhances market protection. Even if the launch is executed through a strategic partner, the early EAP foothold positions Zevra to negotiate favorable distribution and pricing agreements that can accelerate revenue capture. {bullet} The pipeline’s phase‑3 ciliprolol DISCOVER trial, while in early enrollment, offers a high‑impact second asset that could diversify revenue streams and mitigate reliance on a single orphan drug. The company’s targeted outreach to genetic testing centers and vascular specialists is already identifying high‑risk patient cohorts, and the FDA’s special protocol assessment status gives the trial a clear regulatory pathway. Successful demonstration of efficacy would place Zevra in a dual‑disease portfolio, positioning the company as a leader in rare metabolic disorders and opening doors to cross‑selling opportunities with its existing product’s patient services infrastructure. The modest R&D spend relative to the potential upside underscores a favorable risk‑reward profile for the asset. {bullet} Cash runway and debt profile provide a cushion that reduces the need for external financing during the critical ramp‑up phase. The $230 million cash position, combined with only $61 million debt, affords a 12‑month operating reserve that is robust relative to industry peers in the rare‑disease segment. This financial buffer enables Zevra to absorb market volatility, pursue opportunistic acquisitions, or fund contingency plans without diluting shareholder value. Moreover, the company’s disciplined capital allocation framework, emphasizing return on investment over broad burn, signals management’s commitment to shareholder wealth maximization. {bullet} Reimbursement speed improvements, driven by a shift from formulary to medical exception pathways, reveal that the payer mix is evolving in favor of Zevra. The ability to secure high coverage rates through both avenues indicates that the company can navigate the complex U.S. payer landscape without relying on a single insurance partner. This diversified approach enhances pricing leverage and reduces the risk of sudden policy changes. The company’s ongoing engagement with Medicare Part D changes—through proactive gross‑to‑net adjustments—demonstrates a willingness to adapt to payer policy shifts, further mitigating revenue erosion. {bullet} Finally, the company’s focus on patient services, epitomized by Amplify Assist and the consistent refill adherence, creates a lock‑in effect that can translate into sustainable long‑term sales. By ensuring that patients receive monthly refills with minimal friction, Zevra builds a reliable revenue stream that is less susceptible to demand shocks. The emphasis on patient experience also positions the company favorably for future health‑policy initiatives that reward value‑based outcomes, potentially unlocking additional reimbursement pathways.

MyPlayFa’s commercial trajectory in the U.S. demonstrates a clear upside trajectory, with 66% of diagnosed NPC patients achieving covered life status within a single year of launch. The rapid acceleration of reimbursement from months to weeks, even reaching 24‑hour turnaround for certain payers, signals a strengthening payer ecosystem that can sustain high utilization rates. The company’s investment in physician education and an AI‑driven patient‑identification platform is already yielding a higher proportion of newly diagnosed patients, a demographic that can amplify sales volume as awareness spreads across community practices. This momentum, coupled with a disciplined reduction in operating and R&D expenses, has slashed net losses from $33.2 million to a modest $0.01 per share, indicating that cash burn is being tamed while revenue grows. {bullet} The European expansion presents a catalyst that management has under‑promoted but is already gaining traction through the EMA validation and a 92‑patient global EAP. With an estimated 1,100 NPC patients in the region, the potential addressable market exceeds the U.S. base by a factor of 1.2, yet the presence of a mature miglustat therapy provides a receptive environment for a disease‑modifying alternative. A patent term extension request, if granted, could prolong exclusivity beyond orphan exclusivity, giving the company a regulatory shield that enhances market protection. Even if the launch is executed through a strategic partner, the early EAP foothold positions Zevra to negotiate favorable distribution and pricing agreements that can accelerate revenue capture. {bullet} The pipeline’s phase‑3 ciliprolol DISCOVER trial, while in early enrollment, offers a high‑impact second asset that could diversify revenue streams and mitigate reliance on a single orphan drug. The company’s targeted outreach to genetic testing centers and vascular specialists is already identifying high‑risk patient cohorts, and the FDA’s special protocol assessment status gives the trial a clear regulatory pathway. Successful demonstration of efficacy would place Zevra in a dual‑disease portfolio, positioning the company as a leader in rare metabolic disorders and opening doors to cross‑selling opportunities with its existing product’s patient services infrastructure. The modest R&D spend relative to the potential upside underscores a favorable risk‑reward profile for the asset. {bullet} Cash runway and debt profile provide a cushion that reduces the need for external financing during the critical ramp‑up phase. The $230 million cash position, combined with only $61 million debt, affords a 12‑month operating reserve that is robust relative to industry peers in the rare‑disease segment. This financial buffer enables Zevra to absorb market volatility, pursue opportunistic acquisitions, or fund contingency plans without diluting shareholder value. Moreover, the company’s disciplined capital allocation framework, emphasizing return on investment over broad burn, signals management’s commitment to shareholder wealth maximization. {bullet} Reimbursement speed improvements, driven by a shift from formulary to medical exception pathways, reveal that the payer mix is evolving in favor of Zevra. The ability to secure high coverage rates through both avenues indicates that the company can navigate the complex U.S. payer landscape without relying on a single insurance partner. This diversified approach enhances pricing leverage and reduces the risk of sudden policy changes. The company’s ongoing engagement with Medicare Part D changes—through proactive gross‑to‑net adjustments—demonstrates a willingness to adapt to payer policy shifts, further mitigating revenue erosion. {bullet} Finally, the company’s focus on patient services, epitomized by Amplify Assist and the consistent refill adherence, creates a lock‑in effect that can translate into sustainable long‑term sales. By ensuring that patients receive monthly refills with minimal friction, Zevra builds a reliable revenue stream that is less susceptible to demand shocks. The emphasis on patient experience also positions the company favorably for future health‑policy initiatives that reward value‑based outcomes, potentially unlocking additional reimbursement pathways.

Bear case

The heavy reliance on a single orphan drug—MyPlayFa—renders the company vulnerable to reimbursement volatility and payer policy shifts, especially in the context of Medicare Part D’s recent redesign. The $1.2 million true‑up recognized in Q3 indicates that the company is still grappling with accurately forecasting net revenue in a rapidly changing pay‑or system. If payer mix deteriorates or if additional rebate requirements emerge, the net margin could contract sharply, undermining the thin profitability margin and possibly forcing a return to higher burn levels to maintain sales momentum. {bullet} While the European launch is a promising catalyst, regulatory and market acceptance remain uncertain. The EMA review process is still in the 120‑day clock, and any delays or negative findings could postpone the commercial launch, creating a gap between development and revenue generation. Additionally, pricing negotiations in multiple European countries may result in a lower net price than in the U.S., eroding projected margins. The company’s current lack of a concrete commercialization strategy—whether independent or through a partner—adds further uncertainty to the timeline and cost of entry, potentially delaying the realization of a substantial new revenue stream. {bullet} The pipeline’s phase‑3 ciliprolol DISCOVER trial is still in early enrollment, with only 44 of 150 patients recruited. The trial’s success hinges on a narrow patient population with a high risk of severe events, making recruitment a significant bottleneck. If enrollment stalls or if the trial fails to meet endpoints, the company risks losing a critical diversification opportunity, leaving it exposed to the single‑drug business model. Moreover, the resource allocation between commercial activities for MyPlayFa and clinical development for ciliprolol could strain management’s ability to focus on both simultaneously, potentially diluting efforts across both fronts. {bullet} The decision to scale back Olpruva’s promotion, while freeing resources for MyPlayFa, signals that the company is withdrawing from a potentially profitable market segment. The lack of a clear exit strategy for Olpruva, coupled with the ongoing need to maintain patient support services, may continue to generate sunk costs without generating incremental revenue. The company’s inability to monetize Olpruva could represent a missed opportunity for revenue diversification and a source of financial strain if MyPlayFa encounters unforeseen setbacks. {bullet} Despite impressive coverage gains, the company’s current prescription enrollment forms plateau at 137, with only eight new forms in Q3. If the rate of new patient acquisition slows—due to market saturation, clinician fatigue, or competing therapies—the growth trajectory could stall. The company’s messaging around disease awareness appears to rely heavily on physician outreach and AI‑driven analytics; any miscalculation in the effectiveness of these channels could lead to a shortfall in patient acquisition, compressing sales growth. {bullet} Finally, the company’s cash position, while strong, could become a liability if the company misjudges the capital required for a successful European launch or for scaling the patient support infrastructure. A misstep in budgeting for distribution, marketing, or regulatory compliance could force the company to raise additional capital, potentially diluting shareholder value and eroding investor confidence. Coupled with the inherent volatility of the rare‑disease therapeutic market—where price sensitivity and reimbursement uncertainty are high—the company faces a convergence of financial and operational risks that could undermine its growth narrative.

The heavy reliance on a single orphan drug—MyPlayFa—renders the company vulnerable to reimbursement volatility and payer policy shifts, especially in the context of Medicare Part D’s recent redesign. The $1.2 million true‑up recognized in Q3 indicates that the company is still grappling with accurately forecasting net revenue in a rapidly changing pay‑or system. If payer mix deteriorates or if additional rebate requirements emerge, the net margin could contract sharply, undermining the thin profitability margin and possibly forcing a return to higher burn levels to maintain sales momentum. {bullet} While the European launch is a promising catalyst, regulatory and market acceptance remain uncertain. The EMA review process is still in the 120‑day clock, and any delays or negative findings could postpone the commercial launch, creating a gap between development and revenue generation. Additionally, pricing negotiations in multiple European countries may result in a lower net price than in the U.S., eroding projected margins. The company’s current lack of a concrete commercialization strategy—whether independent or through a partner—adds further uncertainty to the timeline and cost of entry, potentially delaying the realization of a substantial new revenue stream. {bullet} The pipeline’s phase‑3 ciliprolol DISCOVER trial is still in early enrollment, with only 44 of 150 patients recruited. The trial’s success hinges on a narrow patient population with a high risk of severe events, making recruitment a significant bottleneck. If enrollment stalls or if the trial fails to meet endpoints, the company risks losing a critical diversification opportunity, leaving it exposed to the single‑drug business model. Moreover, the resource allocation between commercial activities for MyPlayFa and clinical development for ciliprolol could strain management’s ability to focus on both simultaneously, potentially diluting efforts across both fronts. {bullet} The decision to scale back Olpruva’s promotion, while freeing resources for MyPlayFa, signals that the company is withdrawing from a potentially profitable market segment. The lack of a clear exit strategy for Olpruva, coupled with the ongoing need to maintain patient support services, may continue to generate sunk costs without generating incremental revenue. The company’s inability to monetize Olpruva could represent a missed opportunity for revenue diversification and a source of financial strain if MyPlayFa encounters unforeseen setbacks. {bullet} Despite impressive coverage gains, the company’s current prescription enrollment forms plateau at 137, with only eight new forms in Q3. If the rate of new patient acquisition slows—due to market saturation, clinician fatigue, or competing therapies—the growth trajectory could stall. The company’s messaging around disease awareness appears to rely heavily on physician outreach and AI‑driven analytics; any miscalculation in the effectiveness of these channels could lead to a shortfall in patient acquisition, compressing sales growth. {bullet} Finally, the company’s cash position, while strong, could become a liability if the company misjudges the capital required for a successful European launch or for scaling the patient support infrastructure. A misstep in budgeting for distribution, marketing, or regulatory compliance could force the company to raise additional capital, potentially diluting shareholder value and eroding investor confidence. Coupled with the inherent volatility of the rare‑disease therapeutic market—where price sensitivity and reimbursement uncertainty are high—the company faces a convergence of financial and operational risks that could undermine its growth narrative.

Award Type Breakdown of Revenue (2025)

Collaborative Arrangement and Arrangement Other than Collaborative Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	109.62 Bn	27.71	9.13	-
2	REGN	Regeneron Pharmaceuticals, Inc.	73.93 Bn	16.38	5.15	1.99 Bn
3	ALNY	Alnylam Pharmaceuticals, Inc.	40.50 Bn	147.21	12.86	-
4	RVMD	Revolution Medicines, Inc.	27.39 Bn	-24.25	33,000.01	-
5	ZLAB	Zai Lab Ltd	23.74 Bn	-135.44	97.90	0.20 Bn
6	MESO	Mesoblast Ltd	23.66 Bn	-185.34	1,375.67	0.12 Bn
7	RPRX	Royalty Pharma plc	21.54 Bn	27.99	9.06	8.95 Bn
8	ROIV	Roivant Sciences Ltd.	19.92 Bn	-32.48	3,470.34	-

Research Tools